Compare Repligen Corporation Common Stock (RGEN) vs US Foods Holding Corp. Common Stock (USFD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs US Foods Holding Corp. Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while US Foods Holding Corp. Common Stock trades at $98.45 (market cap $21.18B). The key difference: US Foods Holding Corp. Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, US Foods Holding Corp. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and US Foods Holding Corp. Common Stock for 6 Days on average.
| RGEN | USFD | |
|---|---|---|
Market Cap | $11.14B | $21.18B |
Volume | 1,259,263 | 1,065,315 |
Sector | Health | Consumer Staples |
52-Week High | $194.57 | $110.94 |
52-Week Low | $102.87 | $70.05 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $26.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
US Foods (USFD) trades at $97.91, showing modest daily gains of 0.21%. The stock maintains a bullish technical trend with strong moving average support and trades near key resistance at $98. Fundamentally, the company demonstrates solid revenue growth with $39.42B in 2025 sales and improving profitability, though net margins remain thin at 1.81%. Recent business developments include new product launches and conference participation, signaling ongoing operational momentum.
The outlook remains positive with analyst consensus strongly favoring Buy ratings (73%) and a $117 price target suggesting 19% upside. Key opportunities include margin expansion and market share gains, while risks involve competitive pressures and execution challenges in a low-margin industry. The combination of technical strength, fundamental improvement, and Wall Street support positions USFD favorably for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About US Foods Holding Corp. Common Stock
US Foods distributes food and related products to foodservice operators. Its customers include restaurants, healthcare providers, hospitality businesses, government institutions, and educational organizations.
Read more on USFD →
